Journal of Experimental & Clinical Cancer Research (Apr 2023)
Correction: First-in-human phase 1 clinical trial of anti-core 1 O-glycans targeting monoclonal antibody NEO-201 in treatment-refractory solid tumors
- Christopher B. Cole,
- Maria Pia Morelli,
- Massimo Fantini,
- Markku Miettinen,
- Patricia Fetsch,
- Cody Peer,
- William D. Figg,
- Tyler Yin,
- Nicole Houston,
- Ann McCoy,
- Stanley Lipkowitz,
- Alexandra Zimmer,
- Jung-min Lee,
- Miroslava Pavelova,
- Erin N. Villanueva,
- Kathryn Trewhitt,
- B. Brooke Solarz,
- Maria Fergusson,
- Sharon A. Mavroukakis,
- Anjum Zaki,
- Kwong Y. Tsang,
- Philip M. Arlen,
- Christina M. Annunziata
Affiliations
- Christopher B. Cole
- Women’s Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health
- Maria Pia Morelli
- Women’s Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health
- Massimo Fantini
- Precision Biologics, Inc
- Markku Miettinen
- Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health
- Patricia Fetsch
- Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health
- Cody Peer
- Clinical Pharmacology Program, National Cancer Institute, National Institutes of Health
- William D. Figg
- Clinical Pharmacology Program, National Cancer Institute, National Institutes of Health
- Tyler Yin
- Clinical Pharmacology Program, National Cancer Institute, National Institutes of Health
- Nicole Houston
- Women’s Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health
- Ann McCoy
- Women’s Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health
- Stanley Lipkowitz
- Women’s Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health
- Alexandra Zimmer
- Women’s Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health
- Jung-min Lee
- Women’s Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health
- Miroslava Pavelova
- Women’s Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health
- Erin N. Villanueva
- Women’s Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health
- Kathryn Trewhitt
- Women’s Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health
- B. Brooke Solarz
- Women’s Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health
- Maria Fergusson
- Women’s Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health
- Sharon A. Mavroukakis
- Precision Biologics, Inc
- Anjum Zaki
- Precision Biologics, Inc
- Kwong Y. Tsang
- Precision Biologics, Inc
- Philip M. Arlen
- Precision Biologics, Inc
- Christina M. Annunziata
- Women’s Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health
- DOI
- https://doi.org/10.1186/s13046-023-02668-3
- Journal volume & issue
-
Vol. 42,
no. 1
pp. 1 – 2
Abstract
No abstracts available.